Stock Analiz

Prime Medicine, Inc. PRME

Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2022 · data as of November 13, 2026

$4.27Market cap $950M
Open the interactive analysis →

Prime Medicine, Inc. (PRME) is a healthcare company listed in the US with a market value of about $950M. In the twelve months to September 30, 2026 it had revenue of $7M and net income of -$176M, a net margin of -2497.6%.

Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of -2% a year, a 5-year average ROIC of -72%.

About Prime Medicine

Prime Medicine is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2022. Revenue went from $5M in 2020 to $5M in 2025, a decline of about 2.3% a year. It was profitable in 0 of the last 6 years in our data. Its share count rose by 339% over three years (dilution for shareholders). It spends 3468% of revenue on research and development.

Score: 0.6 / 5

Value0/5
Future growth3/5
Track record0/5
Financial health0/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • Profit margin improving
  • Strong R&D investment or growth above 20%

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S134.5
P/B112.6
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-16.7%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)55.3%
Revenue growth (5 yrs, per year)-2.3%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-5454.5%
ROIC (5-yr avg.)-72.2%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 6 years

Fiscal yearTTM202520242023202220212020
Revenue$7M$5M$3M$0$0$0$5M
Net income-$176M-$201M-$196M-$198M-$122M-$165M-$3M
Free cash flow-$159M-$167M-$130M-$174M-$148M-$38M-$6M
EPS (diluted)$-0.98$-1.35$-1.65$-2.18$-4.19$-14.19$-1.91
Net margin-2497.6%-4342.4%-6566.6%———-65.5%
ROIC—-69.4%-82.5%-110.3%-26.7%—-14.6%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 10 analysts is $7.03, 65% above the current price; targets range from $4.25 to $9.00; the consensus rating is “Buy”; expected EPS is $-0.91 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Prime Medicine pay a dividend?

Not currently.

Is Prime Medicine a good stock to buy?

We do not give buy or sell advice. Prime Medicine scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.